Key statistics
On Friday, Pharming Group NV (PHGN:MUN) closed at 0.80, 22.04% above the 52 week low of 0.6555 set on Sep 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.80 |
---|---|
High | 0.80 |
Low | 0.80 |
Bid | 0.8075 |
Offer | 0.8155 |
Previous close | 0.80 |
Average volume | 3.75k |
---|---|
Shares outstanding | 678.35m |
Free float | 662.48m |
P/E (TTM) | -- |
Market cap | 548.71m EUR |
EPS (TTM) | -0.0194 EUR |
Data delayed at least 15 minutes, as of Oct 18 2024 07:05 BST.
More ▼
Announcements
- Pharming Group to report third quarter 2024 financial results on October 24
- Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
- Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
- Pharming Group to participate in September investor conferences
- Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH): Buy
- Pharming Group reports second quarter and first half 2024 financial results and provides business update
- Pharming Group to report second quarter and first half 2024 financial results on August 1
- Pharming Group to participate in June investor conferences
- Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
- Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
More ▼